Arthur G. Taveras

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Ming Liu, Matthew Bryant, Jianping Chen et al. · PubMed · 1998 · 309 citations

Sch 66336, Chemoprevention Strategy, Farnesyl Protein Transferase +15

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models

Vijaykumar M. Baragi, Gabriele Becher, Alison M. Bendele et al. · Arthritis & Rheumatism · 2009 · 171 citations

Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex

Arthur G. Taveras, Stacy Remiszewski, Ronald J. Doll et al. · Bioorganic & Medicinal Chemistry · 1997 · 121 citations

Molecular Docking, Drug Target, Biochemistry +10

Discovery of 2-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123):  A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist

Michael P. Dwyer, Younong Yu, Jianping Chao et al. · Journal of Medicinal Chemistry · 2006 · 113 citations · Full text

Pharmaceutical Science, Drug Target, Immunology +18

The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines

Hena R. Ashar, Linda James, Kimberly Gray et al. · Experimental Cell Research · 2001 · 111 citations

Tumor Biology, G1 Pause, Oncogenic Agent +8